Fluoxetine
- Generic Name
- Fluoxetine
- Brand Names
- Prozac, Sarafem, Symbyax
- Drug Type
- Small Molecule
- Chemical Formula
- C17H18F3NO
- CAS Number
- 54910-89-3
- Unique Ingredient Identifier
- 01K63SUP8D
- Background
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
- Indication
Fluoxetine is indicated for both acute and maintenance treatment of major depressive disorder, obsessive compulsive disorder, and bulimia nervosa; however, it is only indicated for acute treatment of panic disorder independent of whether agoraphobia is present. Fluoxetine may also be used in combination with olanzapine to treat depression related to Bipolar I Disorder, and treatment resistant depression. Fluoxetine is additionally indicated for the treatment of female patients with premenstrual dysphoric disorder (PMDD).
- Associated Conditions
- Alcohol Dependency, Anorexia Nervosa (AN), Bulimia Nervosa, Cataplexy, Depression, Major Depressive Disorder (MDD), Major depressive disorder, recurrent episode, Myoclonus, Obesity, Obsessive Compulsive Disorder (OCD), Panic Disorder With Agoraphobia, Panic disorder without agoraphobia, Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD)
- Associated Therapies
- Maintenance therapy
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
- First Posted Date
- 2011-05-26
- Last Posted Date
- 2018-09-17
- Target Recruit Count
- 2944
- Registration Number
- NCT01360866
- Locations
- 🇺🇦
Research Site, Poltava, Ukraine
Neurophysiologic Monitoring of Antidepressant Treatment
- First Posted Date
- 2011-05-25
- Last Posted Date
- 2011-05-25
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 24
- Registration Number
- NCT01360190
Comparing Omeprazole With Fluoxetine for Treatment of Non Erosive Reflux Disease and Its Subgroups: a Double-blind Placebo-controlled Clinical Trial
- Conditions
- Interventions
- First Posted Date
- 2011-01-04
- Last Posted Date
- 2012-03-06
- Lead Sponsor
- Tehran University of Medical Sciences
- Target Recruit Count
- 144
- Registration Number
- NCT01269788
- Locations
- 🇮🇷
Gasterointestinal endoscopy ward, Amir Alam hospital, Tehran university of medical sciences, Tehran, Iran, Islamic Republic of
A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2019-01-29
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT01243957
- Locations
- 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Evansville, Indiana, United States
Pharmacogenomics Studies of Antidepressants
- Conditions
- Interventions
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01204086
- Locations
- 🇨🇳
National Cheng-Kung University Hospital, Tainan, Taiwan
Biomarkers of Antidepressant Treatment in Adolescents With Major Depression (The Adolescents MDD Study)
- First Posted Date
- 2010-08-20
- Last Posted Date
- 2014-07-03
- Lead Sponsor
- University of California, Los Angeles
- Target Recruit Count
- 26
- Registration Number
- NCT01185977
- Locations
- 🇺🇸
UCLA Semel Institute, Los Angeles, California, United States
Electroacupuncture Combined With Antidepressants for Post-stroke Depression
- Conditions
- Interventions
- First Posted Date
- 2010-08-03
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 43
- Registration Number
- NCT01174394
- Locations
- 🇭🇰
Kowloon Hospital - Department of Rehabilitation, Kowloon, Hong Kong
🇭🇰Kowloon Hospital - Department of Psychiatry, Kowloon, Hong Kong
🇭🇰Tung Wah Hospital - Rehabilitation Unit, Department of Medicine, Hong Kong, Hong Kong
Developing Adaptive Treatment Strategies for Children and Adolescents With Obsessive-compulsive Disorder.
- Conditions
- Interventions
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2014-10-24
- Lead Sponsor
- Roseli Shavitt
- Target Recruit Count
- 144
- Registration Number
- NCT01148316
- Locations
- 🇧🇷
Institue of Psychiatry - Hospital of Clinics - University of São Paulo, São Paulo, Brazil
Fluoxetine in Multiple System Atrophy Patients
- First Posted Date
- 2010-06-17
- Last Posted Date
- 2015-03-26
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 87
- Registration Number
- NCT01146548
- Locations
- 🇫🇷
hospital center of Aix enProvence, Aix en Provence, France
🇫🇷Hospital Gabriel Montpied, Clermont-Ferrand, France
🇫🇷University Hospital Henri Mondor, Creteil, France
Early Prediction of Fluoxetine Response
- First Posted Date
- 2010-02-25
- Last Posted Date
- 2010-02-25
- Lead Sponsor
- Kaohsiung Kai-Suan Psychiatric Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT01075529
- Locations
- 🇨🇳
Kai-Suan Psychiatric Hospital, Kaohsiung, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.